A recent genomic profiling analysis of cholangiocarcinoma harboring FGFR2 fusions or rearrangements showed that co-occurring CDKN2A/B alterations were associated with significantly shortened progression-free survival [34]. This evidence concerns the gene CDKN2A and cholangiocarcinoma.